Preoperative assessment of the resectability of pancreatic ductal adenocarcinoma on CT according to the NCCN Guidelines focusing on SMA/SMV branch invasion
- PMID: 33740095
- DOI: 10.1007/s00330-021-07847-4
Preoperative assessment of the resectability of pancreatic ductal adenocarcinoma on CT according to the NCCN Guidelines focusing on SMA/SMV branch invasion
Abstract
Objectives: For patients with pancreatic adenocarcinoma (PAC), adequate determination of disease extent is critical for optimal management. We aimed to evaluate diagnostic accuracy of CT in determining the resectability of PAC based on 2020 NCCN Guidelines.
Methods: We retrospectively enrolled 368 consecutive patients who underwent upfront surgery for PAC and preoperative pancreas protocol CT from January 2012 to December 2017. The resectability of PAC was assessed based on 2020 NCCN Guidelines and compared to 2017 NCCN Guidelines using chi-square tests. Overall survival (OS) was estimated using the Kaplan-Meier method and compared using log-rank test. R0 resection-associated factors were identified using logistic regression analysis.
Results: R0 rates were 80.8% (189/234), 67% (71/106), and 10.7% (3/28) for resectable, borderline resectable, and unresectable PAC according to 2020 NCCN Guidelines, respectively (p < 0.001). The estimated 3-year OS was 28.9% for borderline resectable PAC, which was significantly lower than for resectable PAC (43.6%) (p = 0.004) but significantly higher than for unresectable PAC (0.0%) (p < 0.001). R0 rate was significantly lower in patients with unresectable PAC according to 2020 NCCN Guidelines (10.7%, 3/28) than in those with unresectable PAC according to the previous version (31.7%, 20/63) (p = 0.038). In resectable PAC, tumor size ≥ 3 cm (p = 0.03) and abutment to portal vein (PV) (p = 0.04) were independently associated with margin-positive resection.
Conclusions: The current NCCN Guidelines are useful for stratifying patients according to prognosis and perform better in R0 prediction in unresectable PAC than the previous version. Larger tumor size and abutment to PV were associated with margin-positive resection in patients with resectable PAC.
Key points: • The updated 2020 NCCN Guidelines were useful for stratifying patients according to prognosis. • The updated 2020 NCCN Guidelines performed better in the prediction of margin-positive resection in unresectable cases than the previous version. • Tumor size ≥ 3 cm and abutment to the portal vein were associated with margin-positive resection in patients with resectable pancreatic adenocarcinoma.
Keywords: General surgery; Guideline; Pancreatic neoplasms; Survival.
© 2021. European Society of Radiology.
Similar articles
-
CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy.Eur Radiol. 2021 Feb;31(2):813-823. doi: 10.1007/s00330-020-07188-8. Epub 2020 Aug 26. Eur Radiol. 2021. PMID: 32845389
-
Pancreatic Cancer CT: Prediction of Resectability according to NCCN Criteria.Radiology. 2018 Dec;289(3):710-718. doi: 10.1148/radiol.2018180628. Epub 2018 Sep 25. Radiology. 2018. PMID: 30251929
-
High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study.Eur Radiol. 2023 Sep;33(9):5965-5975. doi: 10.1007/s00330-023-09584-2. Epub 2023 Mar 29. Eur Radiol. 2023. PMID: 36988715
-
White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part I, AJCC staging system, NCCN guidelines, and borderline resectable disease.Abdom Radiol (NY). 2020 Mar;45(3):716-728. doi: 10.1007/s00261-019-02289-5. Abdom Radiol (NY). 2020. PMID: 31748823 Review.
-
Staging of pancreatic cancer: resectable, borderline resectable, and unresectable disease.Abdom Radiol (NY). 2018 Feb;43(2):301-313. doi: 10.1007/s00261-017-1410-2. Abdom Radiol (NY). 2018. PMID: 29198002 Review.
Cited by
-
Development and validation of an MRI-radiomics nomogram for the prognosis of pancreatic ductal adenocarcinoma.Front Oncol. 2023 Feb 24;13:1074445. doi: 10.3389/fonc.2023.1074445. eCollection 2023. Front Oncol. 2023. PMID: 36910599 Free PMC article.
-
Multimodal treatment combining neoadjuvant therapy, laparoscopic subtotal distal pancreatectomy and adjuvant therapy for pancreatic neck-body cancer: Case series.World J Gastrointest Surg. 2025 Jan 27;17(1):97897. doi: 10.4240/wjgs.v17.i1.97897. World J Gastrointest Surg. 2025. PMID: 39872794 Free PMC article.
-
Pancreas CT assessment for pancreatic ductal adenocarcinoma resectability: effect of tube voltage and slice thickness on image quality and diagnostic performance.Cancer Imaging. 2023 Dec 18;23(1):126. doi: 10.1186/s40644-023-00637-9. Cancer Imaging. 2023. PMID: 38111054 Free PMC article.
-
Why surgeons care about systemic chemotherapy for pancreatic cancer?Hepatobiliary Surg Nutr. 2021 Dec;10(6):860-863. doi: 10.21037/hbsn-21-398. Hepatobiliary Surg Nutr. 2021. PMID: 35004955 Free PMC article. No abstract available.
-
Survival Outcomes According to NCCN Criteria for Resection Following Neoadjuvant Therapy for Patients with Localized Pancreatic Cancer.Ann Surg Oncol. 2025 Feb;32(2):1321-1330. doi: 10.1245/s10434-024-16437-9. Epub 2024 Nov 1. Ann Surg Oncol. 2025. PMID: 39485615
References
-
- De Angelis R, Sant M, Coleman MP et al (2014) Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study. Lancet Oncol 15:23–34 - DOI
-
- White RR, Lowy AM (2017) Clinical management: resectable disease. Cancer J 23:343–349 - DOI
-
- Tempero MA, Malafa MP, Al-Hawary M et al (2017) Pancreatic adenocarcinoma, version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 15:1028–1061 - DOI
-
- Tummers WS, Groen JV, Sibinga Mulder BG et al (2019) Impact of resection margin status on recurrence and survival in pancreatic cancer surgery. Br J Surg 106:1055–1065 - DOI
-
- Ghaneh P, Kleeff J, Halloran CM et al (2019) The impact of positive resection margins on survival and recurrence following resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma. Ann Surg 269:520–529 - DOI
MeSH terms
LinkOut - more resources
Full Text Sources
Medical